EFPIA has submitted its response to the European Commission’s consultation on the Biotech Act, calling for a clear, predictable and supportive EU framework that strengthens Europe’s competitiveness, attracts global investment and keeps high-value research and innovation in Europe.
With Europe’s share of global pharmaceutical R&D and clinical trials in decline, urgent action is needed to build a stronger biotech ecosystem. The Biotech Act can reverse this trend by:
- Strengthening Europe’s IP framework
- Simplifying and harmonising clinical trials
- Ensuring end-to-end regulatory oversight
- Creating a coherent framework for advanced manufacturing
- Expanding funding and investment
- Harnessing digitalisation and AI
Learn more here.
